stockrow
Friday 6 November 2026
Export VERA’s income statement to Excel — free account
Vera Therapeutics, Inc.
VERA Healthcare Biotechnology
- EPS
- −26.7%
- Free cash flow
- −82.5%
- Total debt
- +1.03%
Quarter to June 2026, against a year earlier
29.62
0.52
−1.73%
Follow VERA
Alert me
Vera Therapeutics, Inc. (VERA) Operating cash flow
Vera Therapeutics, Inc.'s operating cash flow for fiscal 2025 was −$241.1M, compared with −$134.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$338.7M. Over the past ten years it has ranged from −$241.1M (fiscal 2025) to −$10.3M (fiscal 2019) — the current reading is the lowest in ten years. Operating cash flow has fallen for 4 consecutive fiscal years. Vera Therapeutics, Inc. ranks 576th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$241.1M | — |
| FY2024 | −$134.7M | — |
| FY2023 | −$92.2M | — |
| FY2022 | −$67.6M | — |
| FY2021 | −$23.7M | — |
| FY2020 | −$34.8M | — |
| FY2019 | −$10.3M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$100.3M | — |
| Mar 2026 | −$106.5M | — |
| Dec 2025 | −$70.0M | — |
| Sep 2025 | −$61.9M | — |
| 23 more quarters | Free account |
Against its own ten years
Low −$241.1M
High −$10.3M
Ten-year median
−$67.6M
Current reading's percentile
14
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $177.2M |
| ADMA ADMA Biologics Inc compare | $140.8M |
| VCEL Vericel Corporation compare | $65.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$36.5M |
| IMNM Immunome, Inc. compare | −$208.8M |
| CLDX Celldex Therapeutics, Inc. compare | −$235.6M |
| VERA Vera Therapeutics, Inc. | −$338.7M |
| BHVN Biohaven Ltd. compare | −$472.5M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$508.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item